Detalles de la búsqueda
1.
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Cardiovasc Diabetol
; 12: 129, 2013 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007456
Resultados
1 -
1
de 1
1
Próxima >
>>